CN112062799B - Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof - Google Patents
Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof Download PDFInfo
- Publication number
- CN112062799B CN112062799B CN202010766868.8A CN202010766868A CN112062799B CN 112062799 B CN112062799 B CN 112062799B CN 202010766868 A CN202010766868 A CN 202010766868A CN 112062799 B CN112062799 B CN 112062799B
- Authority
- CN
- China
- Prior art keywords
- methoxy
- pyrrolizine
- arabinose triazole
- spiroisoxazole
- methanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 title claims abstract description 59
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 67
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- 150000003852 triazoles Chemical class 0.000 claims abstract description 23
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract description 21
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims abstract description 20
- ORIHZIZPTZTNCU-YVMONPNESA-N salicylaldoxime Chemical compound O\N=C/C1=CC=CC=C1O ORIHZIZPTZTNCU-YVMONPNESA-N 0.000 claims abstract description 18
- KVFIIVSRQFOXOX-FMIVXFBMSA-N (2E)-2-[(4-methoxyphenyl)methylidene]-3H-pyrrolizin-1-one Chemical compound C1=CC(OC)=CC=C1\C=C/1C(=O)C2=CC=CN2C\1 KVFIIVSRQFOXOX-FMIVXFBMSA-N 0.000 claims abstract description 17
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims abstract description 16
- -1 arabinose triazole Chemical class 0.000 claims abstract description 12
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000005406 washing Methods 0.000 claims abstract description 10
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000004440 column chromatography Methods 0.000 claims abstract description 9
- 238000000926 separation method Methods 0.000 claims abstract description 8
- 238000006736 Huisgen cycloaddition reaction Methods 0.000 claims abstract description 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims abstract description 5
- 239000003456 ion exchange resin Substances 0.000 claims abstract description 5
- 229920003303 ion-exchange polymer Polymers 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 239000007787 solid Substances 0.000 claims abstract description 5
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 claims description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 27
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 20
- 235000019441 ethanol Nutrition 0.000 claims description 20
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 17
- 238000003756 stirring Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 11
- 239000000243 solution Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 9
- JXGLKOLYBRHCBH-UHFFFAOYSA-N 2,3-dihydropyrrolizin-1-one Chemical compound C1=CC=C2C(=O)CCN21 JXGLKOLYBRHCBH-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 8
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 239000012065 filter cake Substances 0.000 claims description 6
- 230000007935 neutral effect Effects 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003729 cation exchange resin Substances 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- PPJJNXKJCMMXNI-QZXFTFPVSA-N COC1=CC=C(C2C(C(C=CC=C3)=C3OCC3=CN([C@H]([C@@H]([C@H]4O)O)OC[C@@H]4O)N=N3)=NOC2(C2)CN3C2=CC=C3)C=C1 Chemical compound COC1=CC=C(C2C(C(C=CC=C3)=C3OCC3=CN([C@H]([C@@H]([C@H]4O)O)OC[C@@H]4O)N=N3)=NOC2(C2)CN3C2=CC=C3)C=C1 PPJJNXKJCMMXNI-QZXFTFPVSA-N 0.000 claims description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
- 125000000089 arabinosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)CO1)* 0.000 claims description 3
- 206010017758 gastric cancer Diseases 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 3
- 201000011549 stomach cancer Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 8
- 210000004881 tumor cell Anatomy 0.000 abstract description 7
- 230000005764 inhibitory process Effects 0.000 abstract description 5
- 238000010438 heat treatment Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 229940126214 compound 3 Drugs 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- PEERMPFPCWSJLC-UHFFFAOYSA-N 2-prop-2-ynoxybenzaldehyde Chemical compound O=CC1=CC=CC=C1OCC#C PEERMPFPCWSJLC-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 150000008209 arabinosides Chemical class 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000010378 sodium ascorbate Nutrition 0.000 description 2
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 2
- 229960005055 sodium ascorbate Drugs 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- TZFQZYNVECHEHE-XAHCXIQSSA-N (2R,3R,4R)-2-acetyl-2,3,4,5-tetrahydroxypentanoyl azide Chemical compound C(C)(=O)[C@](C(=O)N=[N+]=[N-])(O)[C@H](O)[C@H](O)CO TZFQZYNVECHEHE-XAHCXIQSSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- ODMMNALOCMNQJZ-UHFFFAOYSA-N 1H-pyrrolizine Chemical compound C1=CC=C2CC=CN21 ODMMNALOCMNQJZ-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- YRKZFGQOVYWLAU-KPSVVDOQSA-N COC1=CC=C(C2C(C(C=CC=C3)=C3OCC3=CN([C@H]([C@@H]([C@H]4O)O)OC[C@@H]4O)N=N3)=NOC2(CN2C3=CC=C2)C3=O)C=C1 Chemical compound COC1=CC=C(C2C(C(C=CC=C3)=C3OCC3=CN([C@H]([C@@H]([C@H]4O)O)OC[C@@H]4O)N=N3)=NOC2(CN2C3=CC=C2)C3=O)C=C1 YRKZFGQOVYWLAU-KPSVVDOQSA-N 0.000 description 1
- 102000003846 Carbonic anhydrases Human genes 0.000 description 1
- 108090000209 Carbonic anhydrases Proteins 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000051366 Glycosyltransferases Human genes 0.000 description 1
- 108700023372 Glycosyltransferases Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000006352 cycloaddition reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- POCUPXSSKQAQRY-UHFFFAOYSA-N hydroxylamine;hydrate Chemical compound O.ON POCUPXSSKQAQRY-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 125000003971 isoxazolinyl group Chemical group 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- GWVCIJWBGGVDJJ-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyl-n-(3-methoxypyrazin-2-yl)acetamide Chemical compound COC1=NC=CN=C1N(C(C)=O)S(=O)(=O)C1=CC=C(N)C=C1 GWVCIJWBGGVDJJ-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and a preparation method and application thereof, firstly, (E) -2- (4-methoxy benzylidene) -2, 3-dihydro pyrrolizine-1-one and acetyl arabinose triazole salicylaldoxime are synthesized, then dissolving the compounds in absolute ethyl alcohol, carrying out 1, 3-dipolar cycloaddition reaction, introducing arabinose triazole and isoxazole structures, finally suspending the intermediate compound in methanol, slowly dropwise adding a methanol solution of sodium methoxide under the protection of nitrogen, heating to room temperature for continuous reaction, washing ion exchange resin with methanol, decompressing the filtrate to remove the methanol to obtain a light yellow solid, and carrying out column chromatography separation to obtain the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative. The methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative prepared by the invention has a strong tumor cell inhibition effect, and provides a basis for further application in the medical field.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to a methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative, and a preparation method and application thereof.
Background
Chemical name: (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizin-1-one having the following chemical structural formula:
pyrrolizine is an important component of alkaloids with biological activity, and derivatives thereof are widely applied in the aspects of inflammation diminishing, pain easing, diabetes resistance, sugar anxiety resistance, tumor resistance and the like.
The triazole has aromaticity and abundant electrons in a molecular structure, can interact with enzymes and receptors in organisms by forming hydrogen bonds, and has various biological activities. Glycoside compounds widely exist in organisms and play important physiological functions, and introduction of glycoside into compound molecules can increase water solubility and guidance of the compounds and improve pharmacological properties of the compounds. Recent studies have shown that some compounds containing glycosylated triazole show better inhibition effects on carbonic anhydrase, glycosyltransferase and protein tyrosine phosphatase.
The isoxazoline skeleton is an important pharmacophore in the application of medicines and has obvious physiological and pharmacological activity. In addition, spiroisoxazolines synthesized by 1, 3-dipolar cycloaddition of nitrile oxides to exocyclic double bonds have attracted attention by pharmacologists because of exhibiting some important physiological properties.
The 1, 3-dipolar cycloaddition reaction is the most important method for synthesizing five-membered heterocyclic compounds with good regioselectivity and body selectivity, and is also a more active reaction in heterocyclic pharmaceutical chemistry research. Therefore, the heterocyclic compound has high synthetic value in terms of pharmacology and synthesis angle.
Disclosure of Invention
The invention aims to provide a methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative, a preparation method and application thereof, and the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative is prepared.
In order to achieve the purpose, the technical scheme of the invention is as follows:
the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative is characterized in that the chemical structural formula of the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative is as follows:
wherein-Glu' is an arabinosyl group represented by the formula:
a preparation method of a methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative comprises the following steps:
Further, the ratio of the amount of the 2, 3-dihydropyrrolizine-1-one to the amount of the 4-methoxybenzaldehyde substance is 1:1.
Further, 2-3mL of 40% NaOH aqueous solution was added to 10mmol of 2, 3-dihydropyrrolizin-1-one and 10mmol of 4-methoxybenzaldehyde in 20-30mL of ethanol.
Furthermore, the ratio of the amounts of the (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one, the acetyl arabinose triazole salicylaldoxime and the chloramine T substance is 1:1: 1.2.
Further, the ratio of the amount of (2S,3R,4S,5S) -2- (4- ((2- (4- (4-methoxyphenyl) -1 '-oxo-1' H,3'H,4H spiro [ isoxazole-5, 2' -pyrrolizin ] -3-yl) phenoxy) methyl) -1H-1,2, 3-triazol-1-yl) tetrahydro-2H-pyran-3, 4, 5-triacetate to sodium methoxide species is 1: 2.
Further, the volume ratio of chloroform to methanol in the eluent adopted by the column chromatography separation is 20: 1.
The invention also provides application of the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative in the aspect of antitumor drugs.
The invention provides a methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and a preparation method and application thereof, the preparation method uses a 1, 3-dipole cycloaddition method to introduce an isoxazole ring into a chemical structure of (E) -2- (4-methoxy benzylidene) -2, 3-dihydro pyrrolizine-1-ketone, thereby finally synthesizing a novel methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative. The methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative prepared by the invention has a strong tumor cell inhibition effect, and provides a basis for further application in the medical field.
Drawings
FIG. 1 is a schematic diagram of the chemical structure of the preparation of (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizin-1-one according to the invention;
FIG. 2 is a schematic diagram of a chemical structural formula of a methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative.
Detailed Description
The technical solution of the present invention is further described in detail with reference to the drawings and examples, which should not be construed as limiting the invention.
Isoxazole derivatives have attracted much attention as a class of useful intermediates and as a variety of pharmaceutical activities that they themselves exhibit. The general idea of the invention is to skillfully introduce glucoside with biological activity, 1,2, 3-triazole pharmacodynamic structure and five-membered isoxazole ring into the molecular structure of (E) -2- (4-methoxy benzylidene) -2, 3-dihydro pyrrolizine-1-one, finally prepare the spiroisoxazole-pyrrolizine derivative with the methoxy substituted arabinose triazole structure and improve the pharmacological activity.
The invention relates to a methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative, which has the following chemical structural formula:
wherein-Glu' is an arabinosyl group represented by the formula:
the embodiment provides a preparation method of a methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative, which comprises the following steps:
as shown in fig. 1 and 2, chemical structural formula 1 in fig. 2 is 2, 3-dihydropyrrolizine-1-one, chemical structural formula 2 is 4-methoxybenzaldehyde, and (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one, (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one corresponds to chemical structural formula 3 is generated through reaction.
The amount ratio of 2, 3-dihydropyrrolizine-1-one to 4-methoxybenzaldehyde substance is 1:1, each 10mmol of 2, 3-dihydropyrrolizine-1-one and 10mmol of 4-methoxybenzaldehyde are dissolved in 20-30mL of ethanol, and 2-3mL of 40% NaOH aqueous solution is added.
One example of the present application, synthesis of (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizin-1-one: dissolving 10mmol of 2, 3-dihydropyrrolizine-1-ketone (compound 1) and 10mmol of 4-methoxybenzaldehyde (compound 2) in 20mL of ethanol, adding 2mL of 40% NaOH aqueous solution, stirring at 75 ℃ for 4 hours, then filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-ketone (compound 3).
In another example, the synthesis of (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizin-1-one: dissolving 10mmol of 2, 3-dihydropyrrolizine-1-ketone (compound 1) and 10mmol of 4-methoxybenzaldehyde (compound 2) in 30mL of ethanol, adding 3mL of 40% NaOH aqueous solution, stirring at 85 ℃ for 3 hours, then filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-ketone (compound 3).
In another example, the synthesis of (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizin-1-one: dissolving 10mmol of 2, 3-dihydropyrrolizine-1-ketone (compound 1) and 10mmol of 4-methoxybenzaldehyde (compound 2) in 20mL of ethanol, adding 2mL of 40% NaOH aqueous solution, stirring at 80 ℃ for 3 hours, then filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-ketone (compound 3).
The present application dissolves 2, 3-dihydropyrrolizin-1-one and 4-methoxybenzaldehyde in ethanol, wherein the ethanol is 95% aqueous ethanol. Ethanol is only the reaction solvent and is present in excess. The ethanol is less than 2, 3-dihydropyrrolizine-1-ketone and 4-methoxybenzaldehyde, and is not dissolved, and the molar concentration of the solution is too dilute, so the reaction is slow.
And 2, carrying out dehydration reaction on the acetyl arabinose triazole salicylaldehyde and hydroxylamine hydrochloride to generate the acetyl arabinose triazole salicylaldoxime.
In the embodiment, the preparation of the acetaarabinotriazole salicylaldoxime by the dehydration reaction of the acetaarabinotriazole salicylaldehyde and hydroxylamine hydrochloride comprises the following steps:
suspending acetyl azide arabinose and 2-propargyloxybenzaldehyde in a mixed solvent of dichloromethane and water, heating to 40-44 ℃, and adding sodium ascorbate and CuSO in turn under vigorous stirring4·5H2And O, continuously carrying out reflux reaction for 4-5 hours, stopping the reaction, separating liquid when the solution system of the chemical reaction is cooled to room temperature, and using CH for a water layer2C12Extracting twice, combining organic phases, drying over night by using anhydrous sodium sulfate, carrying out suction filtration, removing the solvent by pressure reduction, and then carrying out flash column chromatography separation to obtain the acetyl arabinose triazole salicylaldehyde;
adding hydroxylamine hydrochloride and water into a reaction bottle, magnetically stirring until the hydroxylamine hydrochloride is dissolved, adding the acetyl arabinose triazole salicylaldehyde and the absolute ethyl alcohol under stirring, violently stirring for 2-3 hours, and adding 20% Na after the reaction is finished2CO3And (3) regulating the pH value of the reaction solution to be neutral, standing and cooling to room temperature to generate a large amount of white precipitate, putting the white precipitate into a refrigerator for a night, filtering under reduced pressure, and drying at room temperature to obtain granular white crystal acetyl arabinose triazole salicylaldoxime.
In this example, the ratio of the amount of the acetyl arabinose triazole salicylaldehyde to the amount of the hydroxylamine hydrochloride species was 4: 5.
For example:
12mmol of acetyl azidoarabinose, 1.60g (10 mmol 1) of 2-propargyloxybenzaldehyde were suspended in 100mL (dichloromethane): (water) ═ 1:1, heating to 40-44 ℃, and adding 0.2mmol of sodium ascorbate and 0.1mmol of CuSO in sequence under vigorous stirring4·5H2And O, continuously carrying out reflux reaction for 4-5 hours, stopping the reaction, separating liquid when the solution system of the chemical reaction is cooled to room temperature (20-30 ℃), and using CH for a water layer2C12Extraction was performed twice (50 mL. times.2),and combining organic phases, drying the organic phases over night by using anhydrous sodium sulfate, performing suction filtration, removing the solvent by pressure reduction, and performing flash column chromatography separation to obtain the acetyl arabinose triazole salicylaldehyde.
Into a 250mL Erlenmeyer flask, 35.6g (0.5mol) of hydroxylamine hydrochloride and 90mL of H were added2And O, magnetically stirring until the hydroxylamine hydrochloride is dissolved (usually stirring by a magnetic stirrer). The arabinofuranotriazole salicylaldehyde (0.4mol) and 50mL of absolute ethanol are weighed into a 250mL conical flask under stirring, and stirred vigorously for 3 hours. After the reaction is finished, 20% Na is used2CO3And (3) adjusting the pH value of the reaction solution to be neutral, standing and cooling to room temperature to generate a large amount of white precipitate, putting the white precipitate into a refrigerator for overnight, filtering under reduced pressure, and drying at room temperature to obtain granular white crystal, namely the acetyl arabinose triazole salicylaldoxime.
It should be noted that, the dehydration reaction of the arabinoside triazole salicylaldehyde and hydroxylamine hydrochloride to generate the arabinoside triazole salicylaldoxime in this embodiment is already a relatively mature technology, and is not described herein again.
And 3, dissolving (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one (compound 3) and acetyl arabinose triazole salicylaldoxime (compound 4) in absolute ethyl alcohol, adding chloramine T, refluxing for 8-12 hours, carrying out 1, 3-dipolar cycloaddition reaction, introducing arabinose triazole and isoxazole structures, recrystallizing with methanol, and drying in vacuum to obtain an intermediate compound 5.
The mass ratio of the (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one, the acetyl arabinose triazole salicylaldoxime and the chloramine T substance is 1:1: 1.2.
In this example, 10mmol (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizin-1-one (compound 3) and 10mmol acetylarabinotriazole salicylaldoxime (compound 4) were dissolved in 30mL of absolute ethanol, 12mmol of chloramine T was added thereto, and the mixture was refluxed for 12 hours to perform 1, 3-dipolar cycloaddition reaction, so as to introduce arabinotriazole and isoxazole structure, and then recrystallized with methanol, to obtain 5((2S,3R,4S,5S) -2- (4- ((2- (4- (4-methoxyphenyl) -1 '-oxo-1' H,3'H,4H spiro [ isoxazole-5, 2' -pyrrolizine ] -3-yl) phenoxy) methyl) -1H-1,2, 3-triazol-1-yl) tetrahydro-2H-pyran-3, 4, 5-triacetate).
As shown in figure 2, the chemical structural formula 3 in the figure is (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one, the chemical structural formula 4 is acetyl arabinose triazole salicylaldoxime, and the chemical structural formula 5 is the generated intermediate compound 5.
The ratio of the amount of compound 5 to the amount of sodium methoxide material in the column chromatography separation is 1:2, and the volume ratio of chloroform to methanol in the eluent used for the column chromatography separation is 20: 1. In this example, 5mmol of compound 5 is suspended in 20mL of methanol, cooled to 0 ℃ with ice water, slowly added dropwise with 0.6mL of a methanol solution of sodium methoxide at a concentration of 1.0mol/L under the protection of nitrogen, reacted at room temperature for 4 hours, monitored by TLC until the starting material point disappears, the system is adjusted to neutral with 732 strong acid styrene cation exchange resin, filtered, the ion exchange resin is washed with methanol, and the filtrate is decompressed to remove methanol to obtain a pale yellow solid, which is separated by column chromatography [ eluent: and obtaining the spiroisoxazole-pyrrolizine derivative 4- (4-methoxyphenyl) -3- (2- ((1- ((2S,3R,4S,5S) -3,4, 5-trihydroxy tetrahydro-2H-pyran-2-yl) -1H-1,2, 3-triazole-4-yl) methoxyl) phenyl) -1'H,3' H,4H spiro [ isoxazole-5, 2 '-pyrrolizine ] -1' -ketone (compound 6) with a methoxyl substituted arabinose triazole structure according to the volume ratio (chloroform: methanol ═ 20: 1) ].
As shown in fig. 2, the generated spiro isoxazole-pyrrolizine derivative with a methoxy-substituted arabinose triazole structure, i.e., compound 6, has a chemical structural formula 6.
The experimental data are as follows: the methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative (compound 6) is light yellow powder, the yield is 33.2%, the melting point is m.p.152-154 ℃, and nuclear magnetic hydrogen spectrum, infrared spectrogram and element analysis data are as follows:
1H NMR(DMSO-d6)δ:7.25-7.54(m,4H,Ar-H),6.78(dd, J=2.1,0.8Hz,1H),6.55(dd,J=4.1,2.3Hz,1H),6.47(s,1H,C=C-H),5.82 (d,J=10.0Hz,1H),5.34(d,J=10.0Hz,1H),8.40(1H,s),7.62 (1H,d,J=6.4H z),7.52~7.53(1H,m),7.35~7.37(1H,m),7.01 ~7.20(1H,m),5.57(1H,d,J=9.6H z),5.26(2H,s),5.20(s, 1H),4.36(1H,t),4.32(d,J=12.8Hz,1H),4.01(1H,dd,J=3.2,10.0 Hz),3.90(d,J=12.8Hz,1H),3.78(1H,t),3.71(s,3H,CH3O),3.67~3.68 (1H,m),3.44~3.46(2H,m).
IR(KBr)v/cm-1 3451,3433,2916,1702,1603,1458,1243,1094, 1048,755
m/e:587(100.0%)。
Anal.calcd.for C30H29N5O8:C,61.30;H,4.99;N,11.91。
in the embodiment, the MTT method is adopted to determine the in-vitro inhibition effect of the compound 6 on different tumor strains, and the determination result of the anti-tumor activity of the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative is as follows:
The test compounds of different concentrations were coarse-screened in 96-well plates and IC was calculated from the resulting inhibition50Values, results are given in the table below.
Table 1 shows that the compound 6 methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative has IC (integrated Circuit) effect on six tumor cell strains50Value of
TABLE 1
In Table 1, the IC of methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative (compound 6) to six tumor cell lines is shown50The values show that the compound 6 has stronger tumor cell inhibition effect on A549 (lung adenocarcinoma cells) and SGC7901 (gastric cancer cells), and provides a foundation for further application in the medical field.
The above embodiments are only intended to illustrate the technical solution of the present invention and not to limit the same, and those skilled in the art can make various corresponding changes and modifications according to the present invention without departing from the spirit and the essence of the present invention, but those corresponding changes and modifications should fall within the scope of the appended claims.
Claims (8)
1. The methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative is characterized in that the chemical structural formula of the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative is as follows:
wherein-Glu' is an arabinosyl group represented by the formula:
2. a preparation method of the methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative according to claim 1, which is characterized by comprising the following steps:
step 1, (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one synthesis: dissolving 2, 3-dihydropyrrolizine-1-ketone and 4-methoxybenzaldehyde in 20mL of ethanol, adding 40% NaOH aqueous solution, stirring for 3-4 hours at 75-85 ℃, then filtering and separating by using a Buchner funnel, washing a filter cake with water, recrystallizing and purifying by using ethanol, filtering and drying to obtain a product (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-ketone;
step 2, carrying out dehydration reaction on the acetyl arabinose triazole salicylaldehyde and hydroxylamine hydrochloride to generate the acetyl arabinose triazole salicylaldoxime, wherein the chemical structural formula of the acetyl arabinose triazole salicylaldoxime is as follows:
step 3, dissolving (E) -2- (4-methoxybenzylidene) -2, 3-dihydropyrrolizine-1-one and acetyl arabinoltriazole salicylaldoxime in absolute ethyl alcohol, adding chloramine T, refluxing for 8-12 hours, performing 1, 3-dipolar cycloaddition reaction, introducing arabinoltriazole and isoxazole structures, recrystallizing with methanol to obtain (2S,3R,4S,5S) -2- (4- ((2- (4- (4-methoxyphenyl) -1 '-oxo-1' H,3'H,4H spiro [ isoxazole-5, 2' -pyrrolizine ] -3-yl) phenoxy) methyl) -1H-1,2, 3-triazol-1-yl) tetrahydro-2H-pyran-3, 4, 5-triacetate;
step 4, (2S,3R,4S,5S) -2- (4- ((2- (4- (4-methoxyphenyl) -1 '-oxo-1' H,3'H,4H spiro [ isoxazole-5, 2' -pyrrolizine ] -3-yl) phenoxy) methyl) -1H-1,2, 3-triazol-1-yl) tetrahydro-2H-pyran-3, 4, 5-triacetate is suspended in methanol, ice water is cooled to-5 ℃ -0 ℃, methanol solution of sodium methoxide is slowly dripped under the protection of nitrogen, the reaction is continued for 3-4 hours after the temperature is increased to room temperature, TLC is used for monitoring until the raw material point disappears, 732 strong acid styrene cation exchange resin is used for regulating the system to be neutral, and filtration is carried out, washing the ion exchange resin with methanol, decompressing the filtrate to remove the methanol to obtain a light yellow solid, and separating by column chromatography to obtain the methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative 6(4- (4-methoxyphenyl) -3- (2- ((1- ((2S,3R,4S,5S) -3,4, 5-trihydroxy tetrahydro-2H-pyran-2-yl) -1H-1,2, 3-triazole-4-yl) methoxy) phenyl) -1'H,3' H,4H spiro [ isoxazole-5, 2 '-pyrrolizine ] -1' -ketone).
3. The preparation method of the spiroisoxazole-pyrrolizine derivative with the methoxy-substituted arabinose triazole structure as claimed in claim 2, wherein the amount ratio of the 2, 3-dihydro-pyrrolizine-1-one to the 4-methoxybenzaldehyde is 1:1.
4. The preparation method of the methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative according to claim 3, wherein 2-3mL 40% NaOH aqueous solution is added after 2, 3-dihydro pyrrolizine-1-one and 10mmol 4-methoxybenzaldehyde are dissolved in 20-30mL ethanol for each 10 mmol.
5. The preparation method of the methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative according to claim 2, wherein the amount ratio of the (E) -2- (4-methoxy benzylidene) -2, 3-dihydro pyrrolizine-1-one, the acetyl arabinose triazole salicylaldoxime and the chloramine T is 1:1: 1.2.
6. The method for preparing spiroisoxazole-pyrrolizine derivatives with methoxy-substituted arabinose triazole structure according to claim 2, wherein the amount ratio of (2S,3R,4S,5S) -2- (4- ((2- (4- (4-methoxyphenyl) -1 '-oxo-1' H,3'H,4H spiro [ isoxazole-5, 2' -pyrrolizin ] -3-yl) phenoxy) methyl) -1H-1,2, 3-triazol-1-yl) tetrahydro-2H-pyran-3, 4, 5-triacetate to sodium methoxide material is 1: 2.
7. The method for preparing the spiroisoxazole-pyrrolizine derivative with the methoxy-substituted arabinose triazole structure as claimed in claim 2, wherein the volume ratio of chloroform to methanol in an eluant used for column chromatography separation is 20: 1.
8. An application of the methoxy substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative in the preparation of anti-lung adenocarcinoma or anti-gastric cancer drugs according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010766868.8A CN112062799B (en) | 2020-08-03 | 2020-08-03 | Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010766868.8A CN112062799B (en) | 2020-08-03 | 2020-08-03 | Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112062799A CN112062799A (en) | 2020-12-11 |
CN112062799B true CN112062799B (en) | 2022-05-06 |
Family
ID=73656793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010766868.8A Active CN112062799B (en) | 2020-08-03 | 2020-08-03 | Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112062799B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112694478A (en) * | 2020-12-24 | 2021-04-23 | 绍兴文理学院 | Nitro-substituted pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289481A (en) * | 2008-06-06 | 2008-10-22 | 四川大学 | Synthesis of N-aryl-3-(4-beta-D-allopyranoside phenyl)-5-formyl isoxazole-4-methane amide |
CN102276673A (en) * | 2011-06-21 | 2011-12-14 | 中国科学院成都生物研究所 | Preparation method of 2-deoxy-beta-D-glucopyranosyl triazole compound |
CN108570086A (en) * | 2018-04-23 | 2018-09-25 | 绍兴文理学院元培学院 | Maleimide derivatives of the triazole structure containing arabinose and the preparation method and application thereof |
-
2020
- 2020-08-03 CN CN202010766868.8A patent/CN112062799B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289481A (en) * | 2008-06-06 | 2008-10-22 | 四川大学 | Synthesis of N-aryl-3-(4-beta-D-allopyranoside phenyl)-5-formyl isoxazole-4-methane amide |
CN102276673A (en) * | 2011-06-21 | 2011-12-14 | 中国科学院成都生物研究所 | Preparation method of 2-deoxy-beta-D-glucopyranosyl triazole compound |
CN108570086A (en) * | 2018-04-23 | 2018-09-25 | 绍兴文理学院元培学院 | Maleimide derivatives of the triazole structure containing arabinose and the preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
Synthesis of New Spiro Isoxazoline-Pyrrolizinone Derivatives via 1,3-Dipolar Cycloaddition of Nitrile Oxide;X.Li,等;《Journal of Heterocyclic Chemistry》;20140131;第51卷(第1期);第274-276页 * |
Also Published As
Publication number | Publication date |
---|---|
CN112062799A (en) | 2020-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108570086B (en) | Maleimide derivatives of the triazole structure containing arabinose and the preparation method and application thereof | |
CN112062799B (en) | Methoxy-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN111943998B (en) | Methyl mercapto substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN111961099B (en) | Methyl-substituted arabinose triazole structure spiro isoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN112028955B (en) | Trimethoxylated arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN111961101B (en) | Spiroisoxazole-pyrrolizine derivative with arabinose triazole structure as well as preparation method and application thereof | |
CN111961100B (en) | Fluorine-substituted arabinose triazole structure spiroisoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN111909230B (en) | Chlorine-substituted arabinose triazole structure spiro isoxazole-pyrrolizine derivative and preparation method and application thereof | |
CN108558968B (en) | Maleimide derivatives of the triazole structure containing glucose and the preparation method and application thereof | |
CN108570085B (en) | Maleimide derivatives of the triazole structure containing xylose and the preparation method and application thereof | |
CN110642864B (en) | Spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
CN110183467B (en) | P-methoxyphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
CN112645957A (en) | Pyridazinone structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof | |
CN108570087B (en) | Maleimide derivatives of the triazole structure containing galactolipin and the preparation method and application thereof | |
CN110759920A (en) | P-methoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
CN110655522B (en) | O-chlorophenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
CN110128445B (en) | P-chlorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
CN110724148B (en) | P-chlorophenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
CN110746431B (en) | P-methylmercapto phenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
CN110790769B (en) | P-methylphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure and preparation method and application thereof | |
CN110256462B (en) | Para-fluorophenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
CN110734442B (en) | 3,4, 5-trimethoxyphenyl substituted spiro [ indazole-pyrazoline ] derivative containing pyrazole structure, and preparation method and application thereof | |
CN110128447B (en) | P-methylphenyl substituted chromone structure-containing spiro [ indazole-isoxazole ] derivative, and preparation method and application thereof | |
CN110759921A (en) | Spiro [ indazole-pyrazoline ] derivative with p-fluorophenyl substituted pyrazole structure and preparation method and application thereof | |
CN112608322A (en) | Methoxy-substituted pyridazinone-structure-containing spiropyrazole-pyrrolizine derivative and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231227 Address after: Room 202-03, No. 301, Hanzhongmen street, Gulou District, Nanjing, Jiangsu 210000 Patentee after: Nanjing Jiuyun Technology Co.,Ltd. Address before: No. 2799, Qunxian Middle Road, Shaoxing City, Zhejiang Province Patentee before: SHAOXING UNIVERSITY YUANPEI College |